When evaluating the developments and complications of a marginally viable premature infant, physicians and parents must work together to decide on treatment that is in the infant’s best interest.
A clinical case shows how medical commercialism poses risks to patients without symptoms who get full body scans. Screening for pre-morbid disease detection is valuable if implemented correctly but calls for physician caution.
Clinical trials for the blood substitute PolyHeme exposed the possibility for ambiguous interpretation of the FDA’s waiver of informed consent for emergency research.